The therapeutic drug monitoring market is set to generate considerable revenue in the upcoming decade. Sales are in line to upsurge from USD 1,203.9 million in 2024 to USD 2,527.9 million by 2034, moving ahead at a CAGR of 7.7% during this period.
| Attributes | Details |
|---|---|
| Industry Size, 2024 | USD 1,203.9 million |
| Industry Size, 2034 | USD 2,527.9 million |
| Value CAGR (2024 to 2034) | 7.7% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
| Attributes | Details |
|---|---|
| By Product | Reagents |
| Industry share in 2024 | 86.4% |
In light of offering simpler and cost-effective procedures, reagent assays are anticipated to gain a substantial industry share during the forecast horizon. Moreover, most of the time, reagent assays are highly accurate and precise. This is due to their ability to maintain high accuracy and produce reproducible results. Hence, reagents are an ideal option among clinicians nowadays.
| Attributes | Details |
|---|---|
| By Drug | Antiepileptic |
| Industry CAGR from 2024 to 2034 | 47.2% |
Having a narrow therapeutic index, antiepileptic drugs have been gaining popularity among healthcare professionals in recent years. Moreover, the increased availability of TDM tests for these drugs is driving up demand for this segment. This availability of tests makes it simpler and easier for healthcare professionals and clinicians to monitor drug levels in the blood and reduce the risk of adverse drug reactions.
The table below presents a compelling forecast highlighting the potential in major countries. The sale of therapeutic drug monitoring is particularly strong in India and Thailand, positioning Asia Pacific as a prominent region in the global industry. Following closely behind, Germany and Brazil are experiencing a gradual increase in demand.
| Countries | CAGR from 2024 to 2034 |
|---|---|
| Brazil | 5.3% |
| Germany | 8.6% |
| United Kingdom | 8.3% |
| India | 7.3% |
| Thailand | 7.2% |
The CAGR for the Brazilian landscape during the forthcoming period is estimated to be 5.3%. The therapeutic drug monitoring market is poised to experience a substantial upsurge owing to various factors that exert a positive influence.
The aging population is a major concern in Brazil nowadays, leading to an increased prevalence of chronic diseases. As people live longer, conditions like diabetes, hypertension, and cardiovascular diseases become more common.
TDM plays a crucial role in managing drug therapies for these chronic illnesses in Brazil. By monitoring drug levels in patients, healthcare providers can optimize dosages, minimize side effects, and enhance treatment outcomes.
The therapeutic drug monitoring market in Germany is projected to demonstrate an impressive CAGR of 8.6% through 2034. The sector is poised to witness a substantial surge on account of several factors.
Germany boasts a well-established regulatory framework governing therapeutic drug monitoring practices. This framework ensures quality, safety, and efficacy. The country’s healthcare infrastructure includes a network of hospital-based laboratories equipped with cutting-edge technologies. These facilities play a pivotal role in TDM implementation.
The therapeutic drug monitoring market in the United Kingdom is anticipated to register a noteworthy CAGR of 8.3% throughout the forecast period, owing to a variety of factors that have a significant impact on its growth trajectory.
A significant number of organ transplant procedures have been observed in the United Kingdom. Immunoassay therapy is becoming crucial post-transplant for preventing organ rejection.
Researchers in the region are actively developing TDM for various diseases. Scientists and healthcare professionals in the United Kingdom are exploring novel biomarkers, innovative technologies, and improved monitoring techniques.
The therapeutic drug monitoring market in India is poised to advance at an impressive CAGR of 7.3% for the entire forecast period. This is driven by a host of factors that exert a positive influence on its growth.
The Indian government has started improving healthcare infrastructure development and promoting TDM awareness in the country. Hospitals, clinics, and laboratories are equipped with state-of-the-art facilities, enabling efficient TDM implementation. Moreover, India’s enlarged pharmaceutical industry has contributed to the demand for therapeutic drug monitoring in recent years.
Thailand is expected to progress at an appreciable CAGR of 7.2% in the therapeutic drug monitoring market. This is fueled by a multitude of factors that contribute to the growing demand for the industry.
The rising incidence of diseases necessitates effective drug management in Thailand. Also, increased investments in healthcare infrastructure by both the government and private entities have expanded the TDM market in the country. Public health awareness campaigns emphasize the importance of personalized medicine, driving patient demand for TDM services in the region.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
In light of offering a variety of therapeutic drug monitoring techniques such as chromatography, immunoassays, and others, stakeholders are expected to gain a substantial industry share during the forecast period. Also, manufacturers are increasingly investing in research and development activities for enhancements. Furthermore, several key therapeutic drug monitoring market players are creating partnerships with educational institutes and pharmaceutical labs.
Recent Development in the Therapeutic Drug Monitoring Market
| Attribute | Details |
|---|---|
| Estimated Industry Size (2024) | USD 1,203.9 million |
| Projected Industry Size (2034) | USD 2,527.9 million |
| Anticipated Growth Rate (2024 to 2034) | 7.7% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Sector Analysis | USD million or billion for Value and Units for Volume |
| Key Regions Covered | North America; Latin America; Europe; Middle East & Africa (MEA); East Asia; South Asia and Oceania |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, Spain, Italy, France, United Kingdom, Russia, China, India, Australia & New Zealand, GCC Countries, and South Africa |
| Key Segments Covered | By Product, By Drug, By Technology, and End User |
| Key Companies Profiled | Abbott Laboratories; bioMérieux SA; F. Hoffmann-La Roche AG; Siemens Healthineers; Thermo Fisher Scientific Inc.; Danaher Corporation; BÜHLMANN Laboratories AG; Sekisui Medical Co., Ltd.; Randox Laboratories Ltd.; Bio-Rad Laboratories, Inc. |
| Report Coverage | Sector Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Sector Dynamics and Challenges, and Strategic Growth Initiatives |
Based on product, the industry is bifurcated into reagents and consumables
Drugs available for therapeutic drug monitoring are antiepileptics, antiarrhythmics, antibiotics, immunosuppressants, and others.
Regarding technology, the industry is classified into immunoassay, liquid chromatography-tandem mass spectrometry, and high-performance liquid chromatography (HPLC)-tandem mass spectrometry.
Top end users operating in this industry are hospitals, diagnostics laboratories, academic & research institutes, and pharmaceutical companies
The industry is analyzed in North America, Latin America, Europe, South Asia, East Asia, Oceania, as well as the Middle East and Africa
The CAGR of the industry in the United States is estimated to be 8.3%.
The industry is expected to progress at a CAGR of 7.7% through 2034.
The industry is expected to be worth USD 1,203.9 million in 2024.
The CAGR of the market in Germany is estimated to be 8.6% through 2034.
The sector is estimated to get as big as USD 2,527.9 million by 2034.
| Market Value for 2024 | USD 1.32 billion |
|---|---|
| Market Value for 2034 | USD 1.97 billion |
| Market Forecast CAGR for 2024 to 2034 | 4.10% |
| Market Valuation (2023) | USD 1.65 billion |
|---|---|
| Market Valuation (2033) | USD 2.69 billion |
| Market CAGR (2023 to 2033) | 5.3% |
| Market Value (2023) | USD 326.7 Billion |
|---|---|
| Market Value (2033) | USD 690.9 Billion |
| Market CAGR (2023 to 2033) | 7.8% |
Explore In-vitro Diagnostics Devices Insights
View Reports
Therapeutic Drug Monitoring Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
